TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03441269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ibuprofen
Description: Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ibuprofen
Description: Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ibuprofen
Description: Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
Study: NCT01332331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan - low dose
Description: body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan - high dose
Description: body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
Study: NCT01342276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vHFC
Description: Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
Study: NCT04671524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: a combination of stretching, range of motion, and strengthening exercise.
Study: NCT03120234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: o.9% normal saline will be used instead of ketamine
Study: NCT01464996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive: OptiBond XTR; Composite: Herculite Ultra
Description: The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive: OptiBond FL; Composite: Herculite Ultra
Description: Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
Study: NCT01118871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir, Ritonavir, Truvada
Description: Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir, Ritonavir and Etravirine
Description: Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
Study: NCT01934244

Intervention type: DEVICE
Intervention: NovaSure Endometrial Ablation
Description: The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
Study: NCT03096483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OEC Elite system
Description: Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
Study: NCT00369707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
Study: NCT03971123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
Study: NCT04233892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-bFGF
Description: CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen/BMMNCs
Description: A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: Patients will receive regular estrogen therapy
Study: NCT01381679

Intervention type: DRUG
Intervention: Ezetimibe
Description: Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
Study: NCT00105066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850mg tablet once a day for one month, then twice a day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet once a day for one month, then twice a day for 3 months
Study: NCT02048540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel oxaliplatin 5-FU CF
Description: docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel oxaliplatin 5-FU CF
Description: docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
Study: NCT03971123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin formulated as AC-LMP-01 50g of AC-LMP-01 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
Study: NCT02048540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Study: NCT01080235

Intervention type: OTHER
Group type: OTHER
Intervention: ABIM Care of Vulnerable Elderly Practice Improvement Module
Description: The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric and Quality Improvement toolkit
Description: A resource toolkit about geriatrics and quality improvement was given to both study arms.

Intervention type: OTHER
Group type: OTHER
Intervention: Geriatric and Quality Improvement toolkit
Description: A resource toolkit about geriatrics and quality improvement was given to both study arms.
Study: NCT00541424

Intervention type: PROCEDURE
Intervention: PET/CT Scanning
Description: Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
Study: NCT03971123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
Study: NCT02784587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
Study: NCT00071032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liberal (10 g/dL) Transfusion Strategy
Description: This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive (Symptomatic) Transfusion Strategy
Description: Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
Study: NCT02903147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Meta-Cognitive Intervention
Description: Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The employer's training
Study: NCT04172220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 1-2 mg of Midazolam as premedication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1-2 mg of Midazolam as premedication.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS
Description: Loco-regional anesthesia: PEC I and serratus plane block with an echoguided technique.~For the PEC I: infiltration of 10 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of the pectoralis major muscle and the small pectoralis muscle at the height of the third rib on the anterior axillary line.~For the serratus plane block: identification of the fifth rib on the average axillary line and infusion of about 20 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of large dorsal muscle and of the anterior serratus muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid-free general anesthesia
Description: Induction with Propofol 1.5-2 mg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in Target-Controlled Infusion (TCI) of 6 mcg/ml, subsequently modified to maintain a Bispectral Index (BIS) value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction with Propofol 1.5-2 mg/kg; Fentanyl 1μg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in TCI of 6 mcg/ml, subsequently modified to maintain a BIS value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia
Description: Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS\>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative analgesia
Description: Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS\>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
Study: NCT03971123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin formulated as AC-1202 60g of AC-1202 (20g caprlic triglyceride) mixed in 240mL dosing liquid at Hour 0 Day 1
Study: NCT04339686

Intervention type: DIAGNOSTIC_TEST
Intervention: Thoracic CT Scan
Description: Retrospective analysis of the thoracic CT scan results compared to final discharge summary
Study: NCT03172819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
Study: NCT01275300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT02956070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Nitrate
Description: The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch \[50%\], lactose monohydrate \[35%\], dibasic calcium phosphate \[14%\], and magnesium stearate \[1%\]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
Study: NCT01275300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin
Study: NCT02215473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate mouth rinse
Description: Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate mouth rinse
Description: Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal instrumentation
Description: Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal instrumentation
Description: Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal instrumentation
Description: Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal instrumentation
Description: Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
Study: NCT02971163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SynDA
Description: SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
Study: NCT03648892

Intervention type: DRUG
Group type: OTHER
Intervention: [c11] raclopride
Description: The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]fallypride
Description: The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
Study: NCT04573738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted transanal total mesorectal excision
Description: Robotic assisted transanal total mesorectal excision for rectal cancer patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic assisted transanal total mesorectal excision
Description: Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
Study: NCT00802906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subthreshold micropulselaser
Description: on demand if leakage is persistent or recurs after initial treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subthreshold micropulselaser
Description: on demand if leakage is persistent or recurs after initial treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 1.5 mg initial intravitreal injection